Chronic constipation
Conditions
Interventions
Test group1:(1) take 1d-linaclotide at 7AM on the day before the procedure, (2)ingested diluted OSS followed by 1L water on the night before the procedure starting at 7 PM, OSS were dissolved in appro
Test group2: (1) take 1d-linaclotide at 7AM two days before the procedure, (2) 1d-linaclotide at 7AM on the day before the procedure, (3) ingested diluted OSS followed by 1L water on the night before
Control group:ingested diluted OSS followed by 1L water on the night before the procedure starting at 7 PM, OSS were dissolved in approximately by 500ml water, and (2) drink 500mL diluted OSS and 1L w
Sponsors
Beijing Shijitan Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Age 18-65 years old; (2) Diagnosis of chronic constipation according to Rome IV criteria must include 2 or more of the following: at least 25% of bowel movements are laborious; At least 25% of bowel movements are dry bulb or hard stool; At least 25% of bowel movements are incomplete; At least 25% of bowel movements have anorectal obstruction and/or blockage; At least 25% of bowel movements require manual assistance, and spontaneous bowel movements < 3 times a week. Loose stools are rare when laxatives are not used. Does not meet diagnostic criteria for irritable bowel syndrome. (3) voluntarily signed written informed consent, including consent to the screening process conducted for the purpose of determining eligibility; (4) The patient can communicate well with the investigator and be able to complete the trial in accordance with the protocol; (5) Can take intestinal cleansing drugs correctly according to the requirements of the project; (6) Follow-up on time.
Exclusion criteria
Exclusion criteria: (1) No indication for full colonoscopy; (2) There are general contraindications to bowel preparation, such as gastrointestinal obstruction, toxic megacolon, surgical acute abdomen including appendicitis, intestinal perforation, acute diverticulitis, etc.; (3) Presence of one of the following diseases: electrolyte disorders, severe heart, liver and kidney diseases, coagulation dysfunction; (4) Have a history of colon surgery; (5) Patients who have taken or previously taken linaclotide or are known to be allergic to linaclotide; (6) Those who are pregnant or plan to become pregnant during the study as determined by pregnancy test; (7) lactating women; (8) Is participating in other clinical observational trials or has participated in other clinical trials within 60 days.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of bowel preparation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Defecation frequency;Caecal intubation rate;Interval between the first OSS and the first defecation;Adenoma detection rate;Colonoscope insertion time and withdrawal time; | — |
Countries
China
Contacts
Public ContactChunmei Guo
Beijing Shijitan Hospital, Capital Medical University
Outcome results
None listed